Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 11/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.69 |
| ▸ | NR3C1 | P04150 | 7/20 | 0.69 |
| ▸ | PGR | P06401 | 6/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.69 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.69 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.69 |
| ▸ | AR | P10275 | 2/20 | 0.69 |
| ▸ | TNF | P01375 | 1/20 | 0.69 |
| ▸ | IL6 | P05231 | 1/20 | 0.69 |
| ▸ | GLUL | P15104 | 1/20 | 0.69 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.69 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | SHBG | P04278 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31723329 | 1.00 | HIF1A (0.69) | HIF1AHSD17B10NR3C1PGRCYP3A4 | |
| SCHEMBL5668344 | 0.93 | HIF1A (0.69) | HIF1AHSD17B10NR3C1PGRCYP3A4 | |
| SCHEMBL1885049 | 0.92 | HIF1A (0.68) | HIF1AHSD17B10NR3C1PGRCYP3A4 | |
| SCHEMBL28612258 | 0.91 | HIF1A (0.67) | HIF1AHSD17B10NR3C1PGRCYP3A4 | |
| SCHEMBL27597463 | 0.91 | HIF1A (0.67) | HIF1AHSD17B10NR3C1PGRCYP3A4 | |
| SCHEMBL22163756 | 0.91 | HIF1A (0.67) | HIF1AHSD17B10NR3C1PGRCYP3A4 | |
| SCHEMBL23736381 | 0.89 | HIF1A (0.65) | HIF1AHSD17B10NR3C1PGRCYP3A4 | |
| SCHEMBL1512721 | 0.89 | HIF1A (0.72) | HIF1AHSD17B10NR3C1PGRCYP3A4 | |
| SCHEMBL2299293 | 0.89 | HIF1A (0.72) | HIF1AHSD17B10NR3C1PGRCYP3A4 | |
| SCHEMBL1182565 | 0.89 | HIF1A (0.72) | HIF1AHSD17B10NR3C1PGRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667057-A2 | TRAILshort ANTIBODY AND METHODS OF USE | Mayo Foundation for Medical Education and Research (US) | 2025-12-24 | — | — | EP | claimed |
| EP-3579860-B1 | TRAILshort ANTIBODY AND METHODS OF USE | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2025-11-12 | — | — | EP | claimed |
| WO-2020263729-A1 | METHOD AND FORMULATION FOR TREATMENT OF WOUNDS BY NEW TISSUE REGENERATION WITH REDUCED TRAUMA AND SCAR TISSUE FORMATION | GALLINA CHARLES (US) | 2020-12-30 | — | — | WO | claimed |
| US-20200397720-A1 | METHOD AND FORMULATION FOR TREATMENT OF WOUNDS BY NEW TISSUE REGENERATION WITH REDUCED TRAUMA AND SCAR TISSUE FORMATION | GALLINA CHARLES HUNTINGTON (US) | 2020-12-24 | — | — | US | claimed |
| CN-110494152-A | Short TRAIL antibody and application method | MAYO FOUND MEDICAL EDUCATION & RES | 2019-11-22 | — | — | CN | claimed |
| US-20190255050-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2019-08-22 | — | — | US | claimed |
| WO-2018148383-A1 | TRAILshort ANTIBODY AND METHODS OF USE | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2018-08-16 | — | — | WO | claimed |
| EP-1945643-A2 | IMIDAZOPYRAZINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-07-23 | — | — | EP | claimed |
| WO-2007058873-A2 | IMIDAZOPYRAZINES AS CYCLIN DEPENTEND KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-05-24 | — | — | WO | claimed |
| US-20260009000-A1 | METHODS FOR TRANSDUCING IMMUNE CELLS | ALLOGENE THERAPEUTICS, INC. (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4667057-A2 | TRAILshort ANTIBODY AND METHODS OF USE | Mayo Foundation for Medical Education and Research (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-3579860-B1 | TRAILshort ANTIBODY AND METHODS OF USE | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12365873-B2 | Methods for transducing immune cells | ALLOGENE THERAPEUTICS, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20250197517-A1 | TRAILshort ANTIBODY AND METHODS OF USE | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-06-19 | — | — | US | disclosed |
| EP-0526566-A1 | TREATMENT OF ERECTILE DYSFUNCTION | Vivus, Inc. (US) | 1993-02-10 | — | — | EP | disclosed |
| WO-1991016021-A1 | TREATMENT OF ERECTILE DYSFUNCTION | ALZA CORPORATION (US) | 1991-10-31 | — | — | WO | disclosed |
| EP-0428573-A1 | METHOD AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF SEPTIC SHOCK. | GENENTECH INC (US) | 1991-05-29 | — | — | EP | disclosed |
| EP-0418297-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF IN TREATING INFLAMMATION. | ALLELIX BIOPHARMA (CA) | 1991-03-27 | — | — | EP | disclosed |
| WO-1990000903-A1 | METHOD AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF SEPTIC SHOCK | GENENTECH, INC. (US) | 1990-02-08 | — | — | WO | disclosed |
| WO-1989011859-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF IN TREATING INFLAMMATION | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1989-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260009000-A1 | METHODS FOR TRANSDUCING IMMUNE CELLS | PBK, ICOS, NFATC1 | HIF1A 2117/4885HSD17B10 4056/4885NR3C1 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.